Improving diagnosis of tumor-induced osteomalacia with gallium-68 DOTATATE PET/CT

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 687-694

  Clifton Bligh, Roderick J ^a,c   Hofman, Michael S ^c,d,k   Duncan, Emma ^e,f   Sim, Ie Wen ^g   Darnell, David ^a   Clarkson, Adele ^h   Wong, Tricia ⁱ   Walsh, John P ^j   Gill, Anthony J ^b,h   Ebeling, Peter R ^d,g   Hicks, Rodney J ^d  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f Melbourne Health   (Australia)

^g GOSFORD HOSPITAL   (Australia)

^h ROYAL HOBART HOSPITAL   (Australia)

ⁱ SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k PETER MACCALLUM CANCER CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCITRIOL; COLECALCIFEROL; FIBROBLAST GROWTH FACTOR 23; GALLUIM TETRAXETAN OCTREOTATE GA 68; PARATHYROID HORMONE; PHOSPHATE; SOMATOSTATIN RECEPTOR 2; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUSTRALIA; BENIGN TUMOR; BONE BIOPSY; BONE PAIN; BONE SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DELAYED DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOPHOSPHATEMIA; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL HISTORY; MINIMAL RESIDUAL DISEASE; ONCOGENIC OSTEOMALACIA; ORTHOPEDIC SURGERY; OSTEOMALACIA; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIB FRACTURE; STRESS FRACTURE; TUMOR LOCALIZATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADULT; AGED; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, CONNECTIVE TISSUE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; OSTEOMALACIA;

EID: 84873655804     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3642     Document Type: Article

References (29)

1. Jan de Beur SM. Tumor-induced osteomalacia. JAMA. 2005;294: 1260-1267.
2. Hesse E, Rosenthal H, Bastian L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. NEngl JMed. 2007;357:422-424.
3. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia- associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Path. 2004;28:1-30.
4. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656-1663.
5. Nelson AE, Bligh RC, Mirams M, et al. Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. 2003;88:4088-4094.
6. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500-6505.
7. White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab. 2001;86:497-500.
8. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87: 4957-4960.
9. Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Rel Cancer. 2011;18:R53-R77.
10. Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet. 2002;359:761-763.
11. Dupond JL, Mahammedi H, Prie D, et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone. 2005;36:375-378.
12. Jagtap VS, Sarathi V, Lila AR, et al. Tumor-induced osteomalacia: a single center experience. Endocr Pract. 2011;17:177-184.
13. Fukumoto S, Takeuchi Y, Nagano A, Fujita T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone. 1999;25:375-377.
14. Nasu T, Kurisu S, Matsuno S, et al. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Intern Med. 2008;47:957-961.
15. Andreopoulou P, Dumitrescu CE, Kelly MH, et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res. 2011;26:1295-1302.
16. van Boekel G, Ruinemans-Koerts J, Joosten F, Dijkhuizen P, van Sorge A, de Boer H. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol. 2008; 158:431-437.
17. Hofmann M, Maecke H, Borner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-1757.
18. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347.
19. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012;56:40-47.
20. Hesse E, Moessinger E, Rosenthal H, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158-162.
21. von Falck C, Rodt T, Rosenthal H, et al. (68)Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. Eur J Nucl Med Mol Imaging. 2008;35:1034.
22. Haeusler G, Freilinger M, Dominkus M, et al. Tumor-induced hypophosphatemic rickets in an adolescent boy-clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. J Clin Endocrinol Metab. 2010;95:4511-4517.
23. Barth JH, Jones RG, Payne RB. 2000 Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomogram. Ann Clin Biochem. 37(Pt 1):79-81.
24. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2:309-310.
25. Zhernosekov KP, Filosofov DV, Baum RP, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007; 48:1741-1748.
26. De Decker M, Turner JH. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm. 2012;27:72-76.
27. Jiang Y, Xia WB, Xing XP, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China. Report of 39 cases and review of the literature. J Bone Miner Res. 2012;27:1967-1975.
28. Elston MS, Stewart IJ, Clifton-Bligh R, Conaglen JV. A case of oncogenic osteomalacia with preoperative secondary hyperparathyroidism: description of the biochemical response of FGF23 to octreotide therapy and surgery. Bone. 2007;40:236-241.
29. Seufert J, Ebert K, Muller J, et al. Octreotide therapy for tumorinduced osteomalacia. N Engl J Med. 2001;345:1883-1888.